WEST LAFAYETTE, Ind., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Alison A. Armour, M.B., Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR, has been appointed as chief medical officer.
"We are excited to welcome Dr. Armour to our team. Her deep clinical and oncology drug development experience will play a key role at Endocyte as we continue to develop and advance our portfolio," said Ron Ellis, president and chief executive officer of Endocyte. "Dr. Armour's knowledge, enthusiasm and leadership capabilities in the medical and radiation field will be of great value to Endocyte as we work to move our pipeline of SMDCs and companion imaging agents through clinical development."
"I am extremely pleased to be joining the Endocyte team. There has never been a more exciting time to be involved in the innovative efforts that are currently changing the cancer treatment landscape," said Dr. Armour. "I am excited to play a role in a company at the forefront of cancer treatment innovation. Endocyte is doing pioneering work in the field of personalised cancer therapy by developing highly targeted SMDC therapeutics and companion imaging agents. I believe these agents will become an important therapeutic strategy in future treatment regimens for patients."
Prior to joining Endocyte, Dr. Armour served as vice president of oncology at Novartis and GSK, where she led the global strategic TYKERB development team in breast cancer and was accountable for a large matrix team composed of clinical, medical, regulatory, statistics, medical affairs, science and commercial colleagues based in multiple sites in the US, UK and Japan. Prior to Novartis and GSK, she was the global medical science director at AstraZeneca and led the development and approval of IRESSA, the first EGFR RTKi registered in first line EGFR mutation positive non-small cell lung cancer.
Before joining industry, Dr. Armour established herself as a thought leader in medical and radiation oncology. Dr. Armour holds her B.Sc. in Biochemistry, M.B., Ch.B. MSc, and Doctorate of Medicine from the University of Glasgow. MRCP at the Member of the Royal College of Physicians Glasgow, and her FRCR at the Royal College of Radiologists London, UK.
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, firstname.lastname@example.org